MAPI PHARMA
Mapi Pharma is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relat... ionships in all of the countries in which it operates. Mapi is dedicated to providing generic and innovative intermediates and APIs, as well as developing finished dosage forms – either for Mapi’s internal API program, as a vertically integrated company, or as generics of leading brands. Mapi is headquartered in Israel. It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel’s designated chemical park. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations.
MAPI PHARMA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2008-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.mapi-pharma.com
Total Employee:
11+
Status:
Active
Contact:
+972732723750
Email Addresses:
[email protected]
Total Funding:
30 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Mylan
Mylan investment in Corporate Round - Mapi Pharma
Shavit Capital
Shavit Capital investment in Post-IPO Equity - Mapi Pharma
Official Site Inspections
http://www.mapi-pharma.com Semrush global rank: 5.69 M Semrush visits lastest month: 1.48 K
- Host name: 172.67.209.221
- IP address: 172.67.209.221
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Mapi Pharma"
Mapi Pharma | Formulations That Meet Unmet Patient Needs
Aug 7, 2023 · Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting …See details»
About - Mapi Pharma
Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting …See details»
Mapi Pharma - Crunchbase Company Profile & Funding
Mapi Pharma is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active …See details»
Press Release Distribution and Management - GlobeNewswire
NESS ZIONA, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative …See details»
Mapi Pharma - LinkedIn
Mapi Pharma is a late clinical stage pharmaceutical company, currently in the final stage of the Phase III with its lead product, GA Depot, a long-acting depot glatiramer acetate for treating...See details»
Mapi Pharma Company Profile 2024: Valuation, …
Developer of proprietary pharmaceuticals designed to depot injectable drugs that are complex formulations in sterile production. The company's pharmaceuticals include life cycle management products, complex active pharmaceutical …See details»
Mapi Pharma - Org Chart, Teams, Culture & Jobs - The Org
View Mapi Pharma's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Mapi Pharma - Quality Assurance and Control - The Org
The Quality Assurance and Control team at Mapi Pharma ensures the development and production of high-barrier to entry and high-added value generic drugs meet regulatory …See details»
Our Strategy - Mapi Pharma
Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting …See details»
Company Mapi Pharma Ltd - MarketScreener.com
Dec 31, 2007 · Mapi Pharma Ltd: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: | NasdaqSee details»
Mapi Pharma - Craft
Mapi Pharma is a company that develops its proprietary pharmaceuticals including life cycle management (LCM) products. It provides Glatiramer Acetate Depot, an injection for the …See details»
Mapi Pharma - Crunchbase
Mapi Pharma and BionPharma focus on developing and commercializing affordable generic drugs, while Apellis Pharmaceuticals specializes in novel therapeutics and drug delivery …See details»
Press Releases - Mapi Pharma
May 31, 2022 · Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on …See details»
ICON Acquires Mapi Group
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has …See details»
Mapi Pharma and Mylan Strengthen Partnership to Develop and
Jun 15, 2020 · Mapi is a clinical stage pharmaceutical company, engaged in the development of high barrier-to-entry and high added-value life cycle management (“LCM”) products that target …See details»
MAPI | Careers at ICON
Mapi is the leading Patient-Centered Research company serving academia, Life Science researchers, and the Pharmaceutical industry. Our commitment to patients is reflected through …See details»
Lead Products - Mapi Pharma
Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting …See details»
Mapi Pharma - Funding, Financials, Valuation & Investors
Mapi Pharma is funded by Shavit Capital. Which investors participated in the most funding rounds?See details»
The Mapi Pharma Group Value added pharmaceuticals
Mapi Pharma GA Depot Phase II RRMS 2 Year Efficacy 81.8% of Patients had No Evidence of Disease Activity Endpoint: Proportion of patients achieving No Evidence of Disease Activity …See details»
Mapi-Pharma Ltd. (Mapi-Pharma Ltd.) - 药物管线_专利_临床试验_ …
卡瑞利珠单抗（camrelizumab）是恒瑞医药研发的人源化抗PD-1单克隆抗体，于2019年5月在中国获批上市，此前已在肺癌、肝癌、食管癌、鼻咽癌以及淋巴瘤五大瘤种中获批了9个适应症。 …See details»